Walleye Capital’s Travere Therapeutics TVTX Stock Holding History

Walleye Capital’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$122K	Sell	4,100 -8,100	-66%	-$242K	﹤0.01%	3591
2025 Q4	$466K	Buy	12,200 +2,500	+26%	+$81.3K	﹤0.01%	3003
2025 Q3	$232K	Buy	9,700 +6,900	+246%	+$130K	﹤0.01%	3217
2025 Q2	$41.4K	Buy	+2,800	New	+$46.4K	﹤0.01%	4096
2024 Q3	–	Sell	-20,700	Closed	-$170K	–	5888
2024 Q2	$170K	Buy	+20,700	New	+$139K	﹤0.01%	4418
2023 Q4	–	Sell	-100	Closed	-$894	–	5538
2023 Q3	$894	Buy	+100	New	+$1.41K	﹤0.01%	4763
2020 Q1	–	Sell	-2,000	Closed	-$28K	–	1676
2019 Q4	$28K	Sell	2,000 -14,500	-88%	-$185K	﹤0.01%	1580
2019 Q3	$191K	Buy	+16,500	New	+$273K	0.01%	1218

Other funds holding TVTX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Walleye Capital's TVTX Position: Q1 2026 in Review

Walleye Capital reduced its Travere Therapeutics (TVTX) stake by 93% in Q1 2026, selling an estimated $151K and leaving 402 shares worth $11.9K. The position accounts for ﹤0.01% of the portfolio, ranked #4133.

Walleye Capital first reported a position in TVTX in Q3 2019 and has held it in 21 quarters since. The position peaked at $11.3M in Q2 2023. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

Walleye Capital held 402 shares of Travere Therapeutics worth $11.9K as of Q1 2026.
Walleye Capital sold 5,052 Travere Therapeutics shares in Q1 2026, an estimated $151K.
Travere Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #4133 holding.
Walleye Capital first reported a position in Travere Therapeutics in Q3 2019 and has held it in 21 quarters since.
Walleye Capital's Travere Therapeutics position peaked at $11.3M in Q2 2023.
260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.